<p>Virtual Reality (VR) biofeedback (BF) may be regarded as a viable means to overcoming barriers of traditional 2D-BF. Combining fully immersive VR-BF with gamification promises to particularly benefit children and adolescents. As data on children is scarce, this multicenter RCT set out to evaluate a self-developed VR-BF game in young patients with stress related disorders. 9–18-year-olds (M<sub>age</sub> = 13.34, SD<sub>age</sub> = 1.99 in the overall sample) with a diagnosis of anxiety and/or mild to moderate depression were randomized to 10-session of heart rate based, fully immersive VR-BF-training (n = 19) or of standard 2D-BF-training (n = 20). Three assessments (baseline, post-training, 3-month-follow-up) were performed for chronic stress, including the two subscales helplessness and self-efficacy (primary outcome), as well as for symptom severity, the ability to relax and health related quality of life (HrQoL; all secondary). Data were analyzed using repeated measures ANOVAs. Improvements in both groups post-treatment and at 3-month-follow-up were found for chronic stress (helplessness and self-efficacy), for emotional symptoms and peer relationship problems, for the ability to relax at school/with peers, and for HrQoL psychological well-being, self-worth, peer- and school-related QoL. Yet, there were no between-group differences regarding treatment outcomes or training-evaluations, and no side effects were detected. These findings imply that VR-BF is as effective as 2D-BF. While this finding is encouraging, it also calls into question the added benefit of VR for this treatment. The design of VR-BF may need critical reevaluation, particularly with regards to reinforcing gamification elements and considering a broader range of physiological signals.</p><p> <?qj left?> <?noindent??><i>Registration of Trial</i>: OSF: osf.io/387wq; German Clinical Trial Registry: DRKS00033887 (<a href="https://drks.de/search/de/trial/DRKS00033887">https://drks.de/search/de/trial/DRKS00033887</a>).</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Virtual reality versus 2D biofeedback for children and adolescents with stress related disorders: a randomized controlled trial

  • Anna Felnhofer,
  • Katharina Goinska,
  • Johann Hattinger,
  • Adrian Kamper,
  • Andreas Lenz,
  • Helmut Hlavacs,
  • Oswald D. Kothgassner

摘要

Virtual Reality (VR) biofeedback (BF) may be regarded as a viable means to overcoming barriers of traditional 2D-BF. Combining fully immersive VR-BF with gamification promises to particularly benefit children and adolescents. As data on children is scarce, this multicenter RCT set out to evaluate a self-developed VR-BF game in young patients with stress related disorders. 9–18-year-olds (Mage = 13.34, SDage = 1.99 in the overall sample) with a diagnosis of anxiety and/or mild to moderate depression were randomized to 10-session of heart rate based, fully immersive VR-BF-training (n = 19) or of standard 2D-BF-training (n = 20). Three assessments (baseline, post-training, 3-month-follow-up) were performed for chronic stress, including the two subscales helplessness and self-efficacy (primary outcome), as well as for symptom severity, the ability to relax and health related quality of life (HrQoL; all secondary). Data were analyzed using repeated measures ANOVAs. Improvements in both groups post-treatment and at 3-month-follow-up were found for chronic stress (helplessness and self-efficacy), for emotional symptoms and peer relationship problems, for the ability to relax at school/with peers, and for HrQoL psychological well-being, self-worth, peer- and school-related QoL. Yet, there were no between-group differences regarding treatment outcomes or training-evaluations, and no side effects were detected. These findings imply that VR-BF is as effective as 2D-BF. While this finding is encouraging, it also calls into question the added benefit of VR for this treatment. The design of VR-BF may need critical reevaluation, particularly with regards to reinforcing gamification elements and considering a broader range of physiological signals.

Registration of Trial: OSF: osf.io/387wq; German Clinical Trial Registry: DRKS00033887 (https://drks.de/search/de/trial/DRKS00033887).